We are considering moving to a stable cell line for our lentiviral production, do you have advice on transfection vs. producer cell line?


While we see the future of LV manufacturing is moving towards the use of a stable cell lines, mainly due to reduction of costs of reagents required for the plasmid/transfection methods currently being used, the length of time (>1 year) to develop such lines and the lower productivity of such systems are the main current hurdles. Transfection based manufacturing process allows one to develop and manufacture in a few weeks time allowing one to test and get their therapeutic product into the pre-clinical and clinical environment much quicker.

Pin It on Pinterest